Labcorp Holdings Inc. (FRA:N6B)
Germany
· Delayed Price · Currency is EUR 230.00
0.00 (0.00%)
Last updated: Aug 15, 2025
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2013 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2013 - 2019 |
| Diagnostics (Dx) | 10.14B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Diagnostics (Dx) Growth | 8.48% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Drug Development | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Drug Development Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | -58.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | 11.63% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biopharma Laboratory Services (BLS) | 2.92B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biopharma Laboratory Services (BLS) Growth | 6.32% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | -58.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | 11.63% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2013 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2013 - 2019 |
| Other | -927.20M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | 0.45% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Diagnostics (Dx) Operating Earnings | 1.61B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Diagnostics (Dx) Operating Earnings Growth | 3.61% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Drug Development Operating Earnings | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Drug Development Operating Earnings Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | -927.20M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | 0.45% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biopharma Laboratory Services (BLS) Operating Earnings | 458.90M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biopharma Laboratory Services (BLS) Operating Earnings Growth | 13.31% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2013 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2013 - 2019 |
| Organic Revenue Growth | 3.90% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| North America % Total Revenue | 87.00 |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| North America % Total Revenue Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe % Total Revenue | 9.00 |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe % Total Revenue Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Geography % Total Revenue | 4.00 |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Geography % Total Revenue Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|